- Home
- ACTG vs ALLO Comparison
ACTG vs ALLO Comparison
Compare ACTG & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACTG | ALLO |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.1M | 452.6M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ACTG | ALLO |
|---|---|---|
| Price | $4.18 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 114.9K | ★ 5.3M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,004,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $255.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.24 | $1.04 |
| 52 Week High | $5.27 | $4.46 |
Technical Indicators
Market Signals| Indicator | ACTG | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 25.84 |
| Support Level | $3.86 | $1.22 |
| Resistance Level | $4.30 | $2.22 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 19.35 | 25.00 |
Price Performance
Historical ComparisonAbout ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations, and Manufacturing Operations. It derives revenue from the Intellectual Property Operations segment. Geographically, it operates in the Americas, Europe, the Middle East and Africa, China, India, and Asia-Pacific.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).